In India, a surge in off-label use of GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight loss has intensified amid rising obesity rates and limited access to approved anti-obesity therapies, prompting urgent safety evaluations by national regulators as of early April 2026.
How GLP-1 and GIP Receptor Agonists Drive Weight Loss in Metabolic Disease
Ozempic and Mounjaro belong to a class of drugs known as incretin mimetics, which enhance the body’s natural glucose-dependent insulin secretion. Semaglutide (Ozempic) acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, slowing gastric emptying and reducing appetite via hypothalamic pathways. Tirzepatide (Mounjaro) uniquely dual-activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, amplifying satiety signals and improving insulin sensitivity more potently than GLP-1 monotherapy. These mechanisms, while effective for glycemic control in type 2 diabetes, are increasingly exploited for cosmetic weight loss in non-diabetic individuals—a trend raising alarms about long-term safety and equity in access.
In Plain English: The Clinical Takeaway
- These drugs reduce hunger and food intake by mimicking gut hormones that signal fullness to the brain.
- Weight loss averages 15-22% over 72 weeks in clinical trials, but benefits require ongoing use and lifestyle support.
- Using them without medical supervision increases risks of severe gastrointestinal side effects, pancreatitis, and potential thyroid tumors.
Epidemiological Surge and Regulatory Lag in South Asia
According to IQVIA India data released in March 2026, prescriptions for semaglutide and tirzepatide in private clinics across Mumbai, Delhi, and Bengaluru increased by 210% year-on-year, with an estimated 68% of users lacking a diabetes diagnosis. This contrasts sharply with regulated pathways in the U.S. FDA and EMA, where these drugs are approved only for type 2 diabetes or, in higher doses (Wegovy, Zepbound), for chronic weight management under strict eligibility criteria. In India, the absence of a formal regulatory framework for anti-obesity pharmacotherapy has enabled unrestricted off-label prescribing, particularly through telemedicine platforms and aesthetic clinics. The Drug Controller General of India (DCGI) issued an advisory on April 5, 2026, warning against unsupervised use but has not yet scheduled these substances under the Drugs and Cosmetics Act.
Clinical Evidence: Efficacy, Adverse Events, and Trial Funding Transparency
The foundational evidence for semaglutide’s weight loss efficacy comes from the STEP program, a series of Phase III trials funded by Novo Nordisk. STEP 1 (NEJM 2021;384:989-1002) demonstrated a mean weight reduction of 14.9% over 68 weeks in 1,961 non-diabetic adults with obesity (BMI ≥30), versus 2.4% with placebo. Gastrointestinal adverse events—nausea, vomiting, diarrhea—occurred in 74% of the semaglutide group, leading to discontinuation in 6.8%. Similarly, tirzepatide’s SURMOUNT-1 trial (JAMA Intern Med 2022;182(11):1123-1136), funded by Eli Lilly, reported up to 22.5% weight loss at 72 weeks with the 15 mg dose, though 12.3% discontinued due to side effects. Both trials excluded individuals with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), contraindications now highlighted in prescribing labels due to rodent studies showing thyroid C-cell hyperplasia.
“The real-world use of these peptides in populations outside trial eligibility—especially young adults seeking rapid weight loss—creates a dangerous disconnect between evidence and practice. We are seeing cases of acute pancreatitis and gallstone disease in patients with no metabolic indication for treatment.”
— Dr. Ranjit Misra, Professor of Endocrinology, All India Institute of Medical Sciences (AIIMS), New Delhi, personal communication, April 12, 2026.
Geo-Epidemiological Bridging: Contrasting Access in High-Income vs. Low- and Middle-Income Settings
In the UK’s NHS, semaglutide for weight loss (Wegovy) remains restricted to specialist weight management services due to cost-effectiveness concerns, with NICE estimating a budget impact of £1.2bn annually if broadly deployed. In contrast, U.S. Medicare Part D coverage for anti-obesity use was expanded in January 2026 following the Treat and Reduce Obesity Act, though prior authorization barriers persist. In India, out-of-pocket costs for a monthly supply of Ozempic range from ₹8,500 to ₹12,000 (~$100–$145 USD), placing it beyond the reach of most without private insurance. This has fueled a black market for diverted or counterfeit products, particularly in urban gray markets. The WHO’s 2025 advisory on substandard and falsified medical products noted a 40% increase in seized semaglutide analogs in Southeast Asia, many lacking active ingredient or containing harmful impurities.
| Parameter | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Primary Mechanism | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Avg. Weight Loss (Phase III) | 14.9% at 68 weeks (STEP 1) | 22.5% at 72 weeks (SURMOUNT-1 15mg) |
| Most Common Side Effects | Nausea (44%), Vomiting (24%), Diarrhea (30%) | Nausea (39%), Vomiting (22%), Diarrhea (31%) |
| Discontinuation Due to AEs | 6.8% | 12.3% |
| Key Contraindications | Personal/family hx MTC or MEN 2, Pregnancy | Same as semaglutide + History of severe GI disease |
| Funding Source | Novo Nordisk | Eli Lilly |
Contraindications & When to Consult a Doctor
These medications are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or prior hypersensitivity to semaglutide or tirzepatide. They should be avoided in pregnant or breastfeeding individuals, those with severe gastroparesis, or a history of pancreatitis. Patients experiencing persistent vomiting, inability to tolerate fluids, severe abdominal pain, or jaundice must seek immediate medical evaluation, as these may indicate pancreatitis, biliary disease, or acute kidney injury secondary to dehydration. Routine monitoring should include thyroid function tests and calcitonin levels if risk factors exist, though routine screening is not recommended for low-risk populations.
The Takeaway: Balancing Innovation with Prudence in Global Obesity Care
The growing demand for Ozempic and Mounjaro in India reflects a global tension between therapeutic innovation and equitable, safe implementation. While these drugs represent a breakthrough in obesity medicine—a condition affecting over 800 million adults worldwide—their off-label use without medical oversight risks eroding public trust and exacerbating health disparities. Regulatory bodies must accelerate frameworks for anti-obesity pharmacotherapy that ensure access for those who necessitate it most, while preventing misuse through clinician education, prescription tracking, and public awareness. Until then, physicians and patients alike must prioritize evidence over expectation, recognizing that sustainable weight management remains rooted in comprehensive lifestyle intervention, with pharmacotherapy as an adjunct—not a replacement—for long-term health.
References
- NEJM. 2021;384:989-1002. Semaglutide once weekly in adults with overweight or obesity.
- JAMA Intern Med. 2022;182(11):1123-1136. Tirzepatide once weekly in adults with obesity or overweight.
- WHO. 2025. Substandard and falsified medical products: Global surveillance report.
- NICE. 2023. Semaglutide for managing overweight and obesity (TA875).
- FDA. 2026. Treat and Reduce Obesity Act implementation update.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or altering any medication regimen. The views expressed are those of the author and do not necessarily reflect the official policy of any institution.
